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Abstract
Drugs that act by inhibiting the renin–angiotensin–aldosterone system (RAAS), such as angiotensin-converting en-
zyme inhibitors (ACE-Is) and angiotensin II receptor type 1 (AT1) blockers (ARBs), have been recognized as a basic 
canon of nephroprotection for years. They are commonly used in monotherapy for glomerulonephritis with pro-
teinuria. At present, they are rarely used in combination therapy in a form of dual blockade of RAAS due to concern 
about possible side effects. On the other hand, both ACE-Is and ARBs are also wrongly referred to as nephrotoxic 
drugs. The significance of therapy with these drugs is seen in evoking acute kidney injury (AKI) or acceleration of 
CKD. The aim of this article was to clarify the opinion on the relationship between ACE-Is or ARBs treatment and 
AKI occurrence, and to attempt to reassess the role of dual RAAS blockade in the treatment of kidney diseases. The 
principles of heart failure (HF) therapy with ACE-Is or ARBs and current data on the importance of RAAS dual 
blockade in hypertension are also discussed.
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Angiotensin-converting enzyme 
inhibitors (ACE-Is) and angiotensin II 
receptor type 1 (AT1) blockers (ARBs) 
and their relationship with acute kidney 
injury (AKI) 
Inhibition of the renin–angiotensin–aldosterone 
system (RAAS) using angiotensin-converting enzyme 
inhibitors (ACE-Is) or angiotensin II receptor type 1 
(AT1) blockers (ARBs) is the basic canon of nephro-
protection that has been used for years in proteinuric 
kidney disease treatment. These drugs inhibit the 
progression of chronic nephropathy to the end stage 
renal failure and increase the time to renal replace-
ment therapy initiation. Both ACE-Is and ARBs 
exhibit multidirectional properties and can improve 
prognosis in patients with coronary artery disease, 
especially after myocardial infarction, hypertensive 
patients or individuals after stroke [1, 2]. Because 
of cardioprotective, angioprotective and nephropro-
tective potential of these drugs, they are often pre-
scribed also in patients with heart failure (HF), with 
both preserved and reduced ejection fraction (EF), 
and coexisting chronic kidney disease (CKD) [3].
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However, there is also a common conviction that 
ACE-Is or ARBs treatment may cause acute kidney 
injury (AKI) or deterioration of pre-existing CKD 
in certain clinical situations. In elderly patients with 
concomitant CKD, after an AKI episode, in popula-
tion with atherosclerotic cardiovascular disease, initi-
ation of ACE-Is or ARBs therapy may cause deterio-
ration of renal function expressed by increased serum 
creatinine level. This is clinical scenario has been 
known for years and has been associated with the 
effect of these drugs on glomerular haemodynamics 
and reduction of intra-glomerular capillary pressure. 
The occurrence of AKI shortly after the commence-
ment of ACE-Is therapy is a well-known diagnostic 
marker for renal artery stenosis. In elderly patients, 
ACE-Is or ARBs treatment should be administered 
with caution, starting with low doses; and prefer-
ably renal artery stenosis should be excluded before 
initiating the treatment in available imaging studies 
(renal arteries Doppler ultrasound or angio-CT).
In spite of primary cause of AKI, discontinuation 
of ACE-Is or ARBs treatment to stop further pos-
sible reduction of glomerular filtration rate, seems 
to be common clinical practice. This approach can 
be justified in patients with hypotension, hypovolae-
mia, in severe general condition, with onset of septic 
or cardiogenic shock. Such individuals require fluid 
resuscitation, starting treatment with catecholamines 
or broad-spectrum antibiotics, discontinuation of 
antihypertensive drugs, intubation and respirato-
therapy or initiation of renal replacement therapy. 
On the other hand, in some patients with AKI, but 
in a good general condition, without hypotension, 
ACE-Is or ARBs treatment should be continued. It 
seems especially important, because increased RAAS 
activity, enhanced inflammation and oxidative stress 
are commonly observed in AKI. Pleiotropic proper-
ties of these drugs and inhibition of inflammation 
and oxidative stress may be considered to be a form 
of prevention of further renal fibrosis after AKI epi-
sode.   
If a decision on discontinuation of ACE-Is or 
ARBs in a patient previously chronically treated with 
one of these drugs has been made, it is important to 
establish, when the treatment should be reapplied as 
well as by whom and where the therapy should be 
conducted (i.e. restarting treatment by a nephrologist 
in the hospital ward or outpatient clinic, resumption 
of treatment by a family doctor). Taking into account 
the long-term benefits of ACE-Is or ARBs adminis-
tration, it seems crucial to reapply this treatment as 
soon as possible. Gayat et al. in analysis of patients 
with AKI (who were hospitalized at Intensive Care 
Unit (ICU)) and were restarted ACE-Is or ARBs 
treatment on the day of ICU discharge, reported 
a statistically significant reduction in 1-year mortal-
ity in the ACE-Is or ARBs group compared with 
patients who did not receive this medication [4]. 
The authors suggest that ACE-Is or ARBs treatment 
should be considered for all patients discharged from 
ICUs as a preventive strategy against cardiovascular 
complications. It should be emphasized that ACE-Is 
or ARBs reintroduction should also be started with 
small doses of the drug, which can be gradually 
increased. Monitoring of serum creatinine level (ex-
pressed as eGFR) and serum potassium level is man-
datory. An increase in creatinine ≥ 30% of baseline 
or a decrease in eGFR ≥ 25% is not an indication 
for discontinuation. An increase in serum creatinine 
concentration in the range of 30–50% can only indi-
cate a need of 50% reduction of the daily dose of the 
drug. An increase in serum creatinine concentration 
> 50% requires discontinuation of the drug. In fact, 
the increase in serum creatinine level after switching 
on the drug indicates that the drug has nephropro-
tective effects, which should be remembered [3].
The exaggerated concern of further deterioration 
of renal function in patients with decompensation 
of congestive heart failure (CHF) may cause in some 
cases ACE-Is or ARBs discontinuation and, what is 
worse, sometimes these agents are not considered in 
further treatment, i.e. in stable period of CHF. In 
these cases, it seems better to continue therapy be-
cause the improvement of heart function as a result 
of ACE-Is or ARBs administration can undoubtedly 
contribute to the improvement of kidney function. 
This issue will be discussed further in this article.
There is also erroneous conviction that ACE-Is or 
ARBs are “nephrotoxic” or “potentially nephrotoxic” 
drugs. Such term can be found, for example, in the 
American Recommendations for the Diagnosis and 
Treatment of AKI. The KDIGO 2012 Guidelines 
(Guideline 4.4.3) recommend clinicians to carefully 
analyse the current pharmacotherapy in patients 
at high risk of AKI (e.g. CKD patients at stages 
G3a–G5) and consider temporary discontinuation 
of ACE-Is or ARBs in some clinical situations, e.g. 
before exposition to contrast agents or exacerbation 
of any concomitant chronic diseases such as already 
mentioned CHF. In the ‘sick day approach’ (sick day 
rules) recommended by the British National Institute 
for Health and Care Excellence (UK NICE Guide-
lines) and popularized among family doctors, it is 
recommended to discontinue ACE-Is, ARBs, met-
formin, diuretics, NSAIDs treatment in any acute 
situation (intercurrent illness) such as vomiting, di-
arrhoea, surgery, or before any medical procedure. 
However, an important question arises whether a pa-
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tient will have the ACE-Is or ARBs reapplied after 
the acute illness is resolved, especially in case of an el-
derly individuals with a high cardiovascular risk. Fre-
quently, this treatment is not restored again, because 
of already mention fear of worsening glomerular 
filtration or hyperkalaemia. It is worth dispelling the 
myth of alleged nephrotoxicity of ACE-Is or ARBs 
as this still commonly used term should be replaced 
by the term: eGFR changes dependent on haemody-
namic changes related with the influence of ACE-Is 
or ARBs. These haemodynamic changes, which are 
commonly known, appear due to the vasodilatation 
effect of these drugs on glomerular arterioles. This 
causes a decrease in intra-glomerular pressure and de-
terioration of glomerular filtration, especially in the 
elderly patients, with CKD and long-lasting hyper-
tension, as well as impaired mechanisms of intrarenal 
blood flow. Therefore, ACE-Is or ARBs cannot be 
referred to as “nephrotoxic” drugs because the effects 
of their haemodynamic activity leading to a decrease 
in eGFR are fundamentally different from, for exam-
ple direct renal tubules damage (direct nephrotoxic 
effect) caused by e.g. aminoglycosides antibiotics, 
radiocontrast agents, antiretroviral drugs or some 
chemotherapeutics drugs (cisplatin analogues) [5–7].
It also seems necessary to re-establish the current 
standards of preventing of contrast induced nephrop-
athy (CIN) in terms of continuation or discontinu-
ation of agents that inhibit the RAAS. CIN is an ex-
ample of iatrogenic AKI that develops within 48–72 
hours after parenteral contrast media administration. 
It is more common in elderly patients with pre-ex-
isting CKD, cardiovascular diseases, diabetes melli-
tus, females and on non-steroidal anti-inflammatory 
drugs (NSAIDs), diuretics or metformin treatment. 
ACE-Is and ARBs are included on the list of drugs 
considered to have adverse effects on CIN course. 
Therefore, in protocols on prevention of CIN occur-
rence or in the Guidelines of Radiological Societies, 
it is recommended to discontinue ACE-Is and ARBs 
48h before exposure to the contrast agent. It seems 
that currently there is no convincing evidence that 
discontinuation of ACE-Is or ARBs prior to exposure 
to the contrast agent may contribute to reducing the 
incidence of CIN. Therefore, this procedure raises 
more and more controversy [8].
Another important clinical problem is the man-
agement of ACE-Is/ARBs in patients undergoing 
surgery (treatment discontinuation vs treatment con-
tinuation). In the analysis of 1594 cases of patients 
undergoing cardiac surgery, Coca et al. compared 
groups of patients in whom ACE-I (or previously 
used ARB) was discontinued on the day of surgery 
and a group of patients in whom such treatment was 
continued. The researchers observed in the postop-
erative period a statistically significant increase in 
the serum creatinine concentration compared to the 
baseline before the surgery, especially in the group 
of patients who continued ACE-Is or ARBs treat-
ment. At the same time, there were no differences 
in the levels of markers of structural kidney damage 
(NGAL, KIM-1, IL-18) between the group of pa-
tients who continued the treatment and the group 
where administration of ACE-I or ARB was stopped. 
The results of these studies indicate that the reduc-
tion of eGFR in patients treated with ACE-Is or 
ARBs is functional, reversible and does not result 
from actually structural kidney damage. Moreover, 
in this group of patients, the appearance of AKI in 
the postoperative period may be related with hypo-
tension resulting from the effect of an aesthetics, 
antibiotic therapy or NSAIDs, used after surgery for 
pain relief [9]. In addition, Whiting et al. in a meta-
analysis of 6 clinical trials (3 randomized trials and 3 
prospective cohort studies) involving 1663 patients 
did not find a justification for a need to discontinue 
ACE-Is or ARBs treatment as an AKI prevention 
strategy in patients undergoing coronary angiogra-
phy or cardiac surgery [10]. Similar conclusions were 
presented by the authors of a meta-analysis pub-
lished in 2018, involving 9 clinical trials in patients 
(n = 6022) previously treated with ACE-I or ARB 
who underwent noncardiac surgery. The authors of 
the meta-analysis compared the strategy based on 
discontinuation of ACE-I or ARB therapy on the 
day of surgery vs. maintenance of ACE-I or ARB 
treatment on the day of surgery and during postop-
erative period. The authors noted a higher incidence 
of hypotension episodes in the perioperative period 
in patients who continued ACE-I or ARB treatment. 
However, no relationship was found between contin-
uation of ACE-I or ARB treatment and the impact 
of this approach on the incidence of cardiovascular 
events and deaths due to cardiovascular causes [11]. 
As the authors conclude, there is a need for random-
ized trials to determine the relationship between the 
use of ACE-Is or ARBs in the pre- and postoperative 
period and the impact of such treatment on cardio-
vascular mortality.
In summary, it can be stated that:
• both ACE-Is and ARBs are not kidney damag-
ing drugs. The mechanisms of their action and 
haemodynamic effects in renal microcirculation 
(decrease in intra-glomerular pressure) cause a re-
versible decrease in glomerular filtration;
• a distinction should be made between functional 
(depending on changes in intrarenal blood flow) 
and structural type of acute kidney injury (AKI) 
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using available biomarkers for early kidney dam-
age, which should be used more widely in clinical 
practice;
• long-term use of ACE-Is as well as ARBs after an 
AKI incident seems to be beneficial and contrib-
utes to a long-term reduction of cardiovascular 
mortality. It is also beneficial in terms of inhibit-
ing kidney fibrosis after the AKI episode and 
constitutes CKD prevention.
Dual RAAS blockade in kidney 
diseases. Is there still a place for it 
in contemporary nephrology? 
Since the introduction of ACE-Is in the 1980s and 
the emergence of ARBs in the mid-1990s, these 
drugs have become the basis for the treatment of pa-
tients with cardiovascular and kidney diseases. Both 
ACE-Is and ARBs have an established position as 
drugs that are a key element of pharmacological 
nephroprotection, especially in groups of patients 
with proteinuric primary glomerulonephritis.
The beneficial effect of both ACE-Is and ARBs 
is associated with not only systemic blood pressure 
decrease, but also intra-glomerular pressure decrease, 
which, as already mentioned, is associated with 
a reduction in proteinuria and halting of glomerular 
filtration rate decline. These two mechanisms play 
a crucial role in preventing progression of chronic 
kidney disease (CKD) to irreversible end-stage phase 
[12]. Simultaneously with haemodynamic effects, 
both ACE-Is and ARBs exert a number of beneficial 
non-haemodynamic actions by limiting inflamma-
tion, inhibiting renal interstitial fibrosis, inhibiting 
platelet aggregation, and apoptosis. Moreover, they 
improve endothelial function. ACE-Is as well as ARBs 
used alone reduce cardiovascular morbidity and mor-
tality in the general population and in patients with 
kidney diseases. The beneficial effects and definite 
advantages over other drugs resulting from blocking 
the RAAS as mentioned earlier, caused that ACE-Is 
and sartans became the basis standard of nephro-
protection. Ground-breaking clinical trials such as 
the REIN study with ramipril (Ramipril efficacy in 
nephropathy), the AASK study (African American 
Study of Kidney Disease and Hypertension), or the 
BENEDICT study (Bergamo nephrologic diabetes 
complication trial) conducted in patients with pri-
mary glomerulopathies with proteinuria and diabetic 
nephropathy, where ACE-Is therapy was used alone, 
showed a clear beneficial effect of ACE-Is on primary 
‘nephrological’ endpoints such as delayed doubling 
of creatinine, delayed progression to the end-stage 
renal failure, or reduction of cardiovascular death 
[13–15]. Equally favourable results were obtained in 
the studies in which ARBs were used (IDNT, RE-
NAAL, DETAIL) [16–18].
On the other hand, it is known that using the 
recommended therapeutic doses of ACE-Is or ARBs 
in monotherapy, it is often impossible to achieve full 
blockade of the RAAS. Inhibition of RAAS activity 
and reduction of the synthesis of e.g. aldosterone are 
usually observed during the first months of ACE-Is 
or ARBs monotherapy. As a result of the aldosterone 
escape phenomenon (aldosterone breakthrough) 
long-term administration of ACE-Is or ARBs does 
not further reduce aldosterone synthesis [8, 9]. It 
seems that this problem affects about 30–50% of 
patients treated with ACE-Is or ARBs. It is presumed 
that one of its mechanisms is hyperkalaemia (as-
sociated with the use of these drugs) that stimulates 
the release of aldosterone or the lack of sufficient 
inhibition of AT II synthesis during ACE-Is therapy 
[19–21].
It is worth remembering that inhibition of angio-
tensin converting enzyme (ACE) causes an increase 
in the synthesis of angiotensin I (AT I), which is con-
verted into angiotensin II (AT II) through a pathway 
independent of the converting enzyme (chymase). 
Comprehensive RAAS control requires a combina-
tion of ACE-I with ARB or the use of other drugs, 
e.g. mineralocorticoid receptor antagonists (MRAs) 
or direct renin inhibitors (DRIs). The association of 
ACE-I with ARB became the basis of the concept of 
so-called dual RAAS blockade. Rarely, although such 
treatment regimens were used in kidney diseases, 
DRI or MRA (triple RAAS blockade) were added to 
the combination of ACE-I with ARB. A method that 
was also used to inhibit the increased activity of the 
RAAS, although it did not find wider application, 
was the use of high doses of ARBs in monotherapy. 
High doses (ultra-high doses) were 2–3 times higher 
than those recommended in the treatment of hy-
pertension and they allowed successful reduction of 
proteinuria [22, 23]. Studies in animal models have 
shown that the use of high doses of ARBs caused 
reversibility of glomerulosclerosis [24].
Dual blockade has its rational premises. It uses 
2  drugs with different mechanisms of action to 
achieve the intended effect — reduction of protein-
uria. It allows the use of slightly smaller doses of each 
drug individually when starting the therapy. On the 
other hand, it allows flexible increase of the dose of 
each drug separately. In turn, dual blockade in which 
an aldosterone antagonist is attached to ACE-I or 
ARB prevents aldosterone escape and limits its ad-
verse effects. Considering the harmful effects of aldo-
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sterone on the cardiovascular system (intensification 
of cardiac and vascular fibrosis) and the fact that it is 
also a recognized factor of the progression of CKD, 
this seems completely justified, but it is not widely 
used due to the risk of hyperkalaemia.
It is worth remembering that the excess of aldo-
sterone causes a weakening of the beneficial effect 
of ACE-Is on left ventricular (LV) hypertrophy (re-
fractory LV hypertrophy) and an impairment of the 
nephrotective effect of ACE-I or ARB monotherapy 
[25]. The benefits of using the dual blockade have 
been found in a number of experimental studies. In 
animal models of diabetic and non-diabetic kidney 
disease, co-administration of ACE-I with sartan was 
shown to be more effective in reducing proteinuria 
and inhibiting structural changes in the kidney, more 
efficiently than when using these drugs alone. Al-
though clinical trials showed a greater reduction in 
proteinuria in dual therapy, there are few data on the 
inhibition of CKD progression to end-stage phase 
due to dual blockade [26, 27].
The first clinical study showing the beneficial ef-
fects of dual therapy based on the combined use of 
ACE-I and ARB was the study with the acronym 
CALM (The candesartan and lisinopril microalbu-
minuria study) conducted in patients with type 2 di-
abetes [28]. Two hundred patients with type 2 diabe-
tes, hypertension and albuminuria, who were treated 
with candesartan 16 mg daily, lisinopril 20 mg dai-
ly or a combination of both, participated in this 
12-week multicentre trial. After 12 weeks of treat-
ment, a beneficial effect of dual therapy i.e. statisti-
cally significant reduction in blood pressure and pro-
teinuria (urinary albumin/creatinine ratio) compared 
to treatment with lisinopril or candesartan alone was 
found. The results of this study and the subsequent 
CALM2 study formed the basis for widespread use 
and recommendation of RAAS dual blockade in ne-
phrology. This type of management was common for 
many years in patients with glomerulonephritis with 
proteinuria. The results of three studies, ONTAR-
GET, ALTITUDE and VA-NEPHRON-D, reduced 
the enthusiasm with which the dual blockade was 
used in kidney diseases.
In the ONTARGET (Ongoing Telmisartan Alone 
and in combination with ramipril global endpoint 
trial) study, which involved 25 620 patients with car-
diovascular disease, the effects of ramipril and telmis-
artan monotherapy were compared to dual blockade 
with both agents. In the dual treatment group, there 
was a greater reduction in blood pressure and a great-
er decrease in albuminuria. On the other hand, an 
increased incidence of hypotension and AKI (includ-
ing the need for renal replacement therapy) as well as 
an increased incidence of life-threatening hyperkalae-
mia were found. At the same time, no differences in 
cardiovascular mortality between the dual blockade 
and monotherapy with ramipril or telmisartan were 
demonstrated [29].
However, the ALTITUDE (The Aliskiren Trial 
in Type 2 Diabetes Using Cardiorenal Endpoints) 
study, comparing the effectiveness of the combina-
tion of aliskiren with ACE-I or ARB versus ACE-I or 
ARB monotherapy in patients with diabetic kidney 
disease and proteinuria was prematurely terminated 
due to occurrence of kidney function deterioration, 
hypotension and hyperkalaemia in 69% in patients 
treated with aliskiren (dual blockade arm) [30].
In the VA-NEPHRON-D (Veterans Affairs Ne-
phropathy in Diabetes) study, in a group of patients 
with diabetic nephropathy with proteinuria in the 
course of type 2 diabetes in which concomitant 
treatment: losartan with lisinopril was used, 34% 
reduction in the risk of glomerular filtration de-
cline, reaching end-stage CKD or death compared 
to the losartan monotherapy was found. However, 
no statistical significance was achieved (p = 0.07), 
perhaps due to the fact that this study was prema-
turely terminated because of more frequent AKI 
and hyperkalaemia incidents in the dual blockade 
group [31]. 
Negative results of these clinical trials resulted 
in a decrease in interest in the treatment based on 
RAAS dual blockade. The last two mentioned studies 
were prematurely terminated due to numerous side 
effects in the dual therapy group. The shortening of 
the study duration provided for in the protocol does 
not allow determining the role of dual therapy in in-
hibiting CKD progression. These studies also showed 
no difference in cardiovascular mortality between the 
RAAS dual blockade group and the monotherapy 
group.
The results of these clinical trials resulted in a re-
duction and eventually discontinuation of the use 
of dual blockade, which was also included in the 
warnings issued in the United States by the Food and 
Drug Administration (FDA, 2012) and in Europe by 
the European Medicines Agency (EMA, 2014).
The key to understanding the adverse results of 
the aforementioned clinical trials, i.e. increasing the 
frequency of side effects in the dual blockade group, 
is selection of the study population. Elderly patients 
with high cardiovascular risk, including heart failure, 
patients susceptible to hypotension, on concomitant 
diuretic therapy, participated in these studies, in par-
ticular in the Ontarget study. In the Ontarget trial, 
24% of patients enrolled in the study had CKD. The 
selection of the study population may have contrib-
arterial hypertension 2020, vol. 24, no. 2
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Treatment with RAAS-blocking drugs 
in patients with heart failure
Heart failure (HF) is a set of symptoms that may be 
accompanied by abnormalities in physical exami-
nation due to changes in the structure and/or func-
tion of a heart. The prevalence of HF, depending 
on the adopted definition, is estimated at 1–2% 
of the adult population in developed countries. 
In the age group over 70 it affects over 10% of 
the population [34]. Heart failure is a significant 
medical, social and economic problem. Despite 
modern therapy, the prognosis of patients with HF 
remains poor. 
The goals of treatment in patients with HF in-
clude improving their clinical condition, exercise 
capacity and quality of life, preventing hospitaliza-
tions and reducing total mortality rate. ACE-Is 
were shown to reduce mortality and morbidity 
in patients with HF especially  with reduced left 
ventricular ejection fraction (HFrEF) and are rec-
ommended for all symptomatic patients who have 
no contraindications and intolerance. In addition, 
ACE-Is are recommended in people with asymp-
tomatic left ventricular systolic dysfunction to re-
duce the risk of developing HF, hospitalization due 
to HF and death [34].
Undoubtedly, the CONSENSUS study turned 
out to be a breakthrough for drugs of this group. 
The program involved 253 patients with conges-
tive heart failure in NYHA class IV, randomized 
to enalapril or placebo. Six months later, the study 
was discontinued after 44% mortality in the pla-
cebo group and 26% in the enalapril group [35]. 
If ACE-Is are not tolerated or are contraindicat-
ed, ARBs should be used in these patients [34]. 
There are some restrictions regarding the use of 
ACE-Is and ARBs in patients with HF accom-
panied by AKI or CKD. Patients with eGFR 
< 30 mL/min/1.73 m2 were excluded from clini-
cal trials; therefore, in this group of patients there 
is no therapy with proven effectiveness based on 
scientific evidence [34]. 
HF is a risk factor for the development of CKD 
and these two conditions often coexist. Approxi-
mately 1/3 of patients with heart failure have mild 
to moderate CKD and about 1/4 of them have 
worsening renal function (WRF) during hospital-
ization due to heart failure [36]. While CKD is an 
independent risk factor for adverse prognosis in 
patients with HF, the importance of transient WRF 
in patients hospitalized for heart failure has not 
been fully established. In a meta-analysis by Dam-
man et al. [37] involving over one million patients 
uted to the adverse results, i.e. the mentioned adverse 
effects in the RAAS dual blockade arm. The ON-
TARGET post hoc analysis showed a reduction in 
proteinuria in the dual blockade arm, but only 13% 
of participants had albuminuria and 4% — protein-
uria. This study was assumed to be a study in a group 
of patients with high cardiovascular risk, and it was 
not a strict sense study evaluating already mentioned 
nephrological hard endpoints. Dual blockade of 
the RAAS (despite the aforementioned restrictions) 
should still be considered in the treatment of kidney 
diseases and it is worth to return to it again. How-
ever, this is not a treatment that can be offered to 
every patient with CKD. It is reasonable to consider 
RAAS dual blockade treatment only in a group of 
carefully selected patients [32]. Clinical situations in 
which the dual blockade of RAAS can be offered are 
shown in Table 1.
Finally, it is worth mentioning that in 2016 Pa-
levsky et al. published a re-analysis of the mentioned 
VA-NEPHRON-D study. The authors again dem-
onstrated an increased incidence of AKI in patients 
receiving combination therapy (ACE-I + ARB) com-
pared to monotherapy, but at the same time the 
dual treatment group showed faster renal function 
recovery, lower cardiovascular mortality and a lower 
risk of progression of kidney disease [33].
To sum up, RAAS dual blockade undoubtedly 
allows further reduction of proteinuria and has an 
advantage in this regard over monotherapy. On the 
other hand, there is no clear data from available 
clinical trials showing its effect on “renal” hard end-
points such as doubling of creatinine, time to start-
ing dialysis or cardiovascular mortality. However, 
taking into account the role of proteinuria in the 
intensification of renal fibrosis processes and un-
doubtedly in the progression of CKD, all actions 
aimed at reducing proteinuria including the use of 
a dual blockade in the selected groups of patients 
should be considered. 
Table 1. Clinical situations in which it is reasonable to consider 
the dual blockade of RAAS, in case of ineffectiveness of monothe-
rapy in kidney diseases patients 
1. Younger patients (no reduction of proteinuria on monotherapy with 
RAAS inhibitors and failure to achieve target blood pressure values)
2. Patients with non-diabetic glomerulopathies
3. Concomitant hypertension
4. Diagnosed albuminuria/proteinuria
5. Preserved renal excretory function 
6. Excluded renal vascular disease
7. High level of patient’s adherence to a low-potassium diet
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with heart failure, 32% of patients had CKD asso-
ciated with a 2-fold increased risk of mortality due 
to any cause. In an additional analysis of approxi-
mately 50 000 patients with HF, WRF occurred 
in 23% of hospitalized patients and was associated 
with a 1.5-fold higher risk of death due to any 
cause. CKD, diabetes, hypertension and the use of 
diuretics were proved to be significant risk factors 
for WRF in these patients [37]. In the literature, 
there are many definitions of WRF based on vari-
ous absolute and relative values of serum creatinine 
increase [36]. The prognostic significance is not 
only the deterioration of kidney function in these 
patients but above all — its duration. In some hos-
pitalized patients, WRF can only be of a temporary 
nature resulting from intensive therapy and does 
not necessarily indicate a worse prognosis for these 
patients [36].
In order to determine whether the WRF is tem-
porary or permanent, Sheerin et al. [38] recommend 
that WRF is evaluated in patients with acute heart 
failure during hospitalization as well as for 3 months 
following discharge from hospital. WRF definition 
should differentiate the temporary decrease in glo-
merular filtration resulting from, among others, used 
pharmacotherapy and adequate response to treat-
ment accompanied by clinical improvement [39]. 
In contrast to the chronically persistent decline in 
glomerular filtration as a result of, among others, too 
intensive treatment with a loop diuretic leading to 
haemodynamic and neurohormonal disorders and, 
as a consequence, to the development of cardiorenal 
syndrome (Fig. 1).
Deterioration of renal function occurs relatively 
often in patients with HF, when starting therapy 
with RAAS inhibitors and during further increase 
in their doses [34]. However, this should not dis-
pose physicians to stop therapy with these drugs, 
as they provide long-term clinical benefits [40]. 
In a study conducted by Testani et al. [41] in the 
group of patients with left ventricular dysfunc-
tion, early WRF, in the subgroup where ACE-I – 
enalapril was included in the treatment, no adverse 
prognostic significance was reported in contrast to 
the subgroup of patients with early WRF receiv-
ing placebo. In the placebo group, early WRF was 
associated with significantly increased mortality. 
A meta-analysis conducted by Clark et al. [40] 
covering over 20 thousand patients with left ven-
tricular systolic dysfunction showed that in the 
group of patients in whom WRF was observed after 
initiating treatment with RAAS inhibitors, a sig-
nificantly higher reduction in total mortality was 
found compared to the group of patients without 
WRF. Consequently, the WRF is not a prognosti-
cally homogeneous syndrome. Therefore, mecha-
nism underlying WRF in patients with HF has 
a major prognostic significance.
Figures 2 and 3 present a practical approach to 
the treatment of patients with chronic heart failure 
and associated renal impairment, including ACE-Is 
or ARBs in therapy.
Figure 1. Forms of worsening renal function (WRF) in patients with heart failure (HF) [36]
Adequate response to applied 
treatment
No response to applied 
treatment 
Transient WRF (pseudo WRF) Persistent WRF (true WRF)
No inuence on prognosis
Worsening the prognosis 
in patient with HF
Hospital due to HF
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Role of dual RAAS blockade 
in hypertension treatment
Drugs from the ACE-Is or ARBs group constitute 
an essential component of first-line antihyperten-
sive therapy in the basic treatment algorithm [42]. 
Both classes of drugs are the most commonly used 
antihypertensive drugs. The use of ARBs is associat-
ed with a significantly lower percentage of patients 
discontinuing treatment due to side effects com-
pared to other classes of drugs and with a similar 
frequency of drug discontinuation compared to pla-
cebo [43]. According to the ESH/ESC guidelines 
for the management of hypertension (2018) and 
the guidelines of the Polish Society of Hypertension 
(2019), the simultaneous use of ACE-Is and ARBs 
is not recommended.
RAAS blockade treatment in the era 
of coronavirus disease 2019 (Covid-19)
It is worth to mention that human severe acute respi-
ratory syndrome coronavirus 2 (SARS-Cov-2) binds 
to target cells through angiotensin-converting en-
zyme 2 (ACE-2) which expression can be found in re-
spiratory epithelium and in epithelial cells of intestine, 
kidney, and blood vessels. The expression of ACE-2 is 
substantially increased in patients with diabetes mel-
litus, hypertension, cardiovascular diseases who are 
treated with ACE-Is or ARBs. Angiotensin-converting 
enzyme 2 expression can also be increased by ibu-
profen and thiazolidinediones. It was hypothesized 
that diabetes and hypertension treatment with ACE-2 
stimulating drugs can be responsible for bad prognosis 
in COVID-19. There were even some suggestions that 
Figure 2. Practical approach to the treatment of patients with chronic heart failure (CHF) accompanied by impaired renal function — inclu-
sion/intensification of ACE-Is or ARBs treatment. WRF — worsening renal function [37]
Yes
Yes Yes
 No (WRF) 
No improvement
Improvement
No 
Monitor creatinine and ionogram at least
every 6 months
Start treatment 
or increase 
the ACE-I/ARB dose
Creatinine increase 
< 50% and creatinine
concentration 
not exceeding 266 umol/L 
(3 mg/dL) or eGFR is not
2
below < 25 mL/min/1.73 m
Pseudo WRF, 
conrm changes 
and regularly monitor
creatinine and ionogram
Reduce the ACE-I/ARB
dose by half or suspend
ACE-I/ARB administration if
(hyperkalemia > 5.5 mmol/L, 
increase in creatinine 
> 100% from baseline 
or > 310 umol/L (3.5 mg/dL)/
2
/eGFR < 20 mL/min/1.73 m )
Pseudo WRF
consider restarting 
ACE-I/ARB treatment, 
consider reducing
the dose of diuretic
True WRF
Discontinue ACE-I/ARB treatment if you reduced 
the dose by half, stop other nephrotoxic drugs, 
consider other causes of worsening kidney function 
(e.g. renal artery stenosis), refer the patient to a consultation 
with a nephrologist
Stable kidney function
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calcium channel blockers which do not act on RAAS 
should be first-line agents in hypertensive patients dur-
ing COVID-19 pandemic [44]. On the other hand, 
ACE-2 can be protective agent and in animal model of 
severe lung injury, ACE-Is or ARBs treatment inhibits 
the extent of lung injury. Reynolds et al. did not find 
any association between ACE-Is or ARBs treatment 
and severe clinical course of Covid-19 [45]. The same 
conclusion was made by Mehra et al. who did not con-
firm previous concerns regarding a potential harmful 
association of ACE inhibitors or ARBs with increased 
in-hospital mortality in COVID-19 [46]. The ACE-Is 
and ARBs usage is more frequent among patients with 
COVID-19 because they are mainly older patients 
with higher prevalence of cardiovascular disease. There 
is a lack of evidence that ACE-Is or ARBs affect the 
risk of COVID-19 [47, 48]. An official ESH state-
ment on COVID-19 from 15th April 2020 concerning 
ACE-Is or ARBs treatment in COVID-19 pandemic 
strongly suggests no need for discontinuation of such 
treatment in stable patients with COVID-19 infection 
or at risk for COVID-19 infection. The treatment 
with ACE-Is and ARBs should be executed accord-
ing to the recommendations in the 2018 ESC/ESH 
guidelines [49]. 
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